世界中の市場調査レポートを販売!当社に無いレポートもお探しします。

レポートナンバー 0000029350

免疫アッセイ市場−2026年までの世界予測

MarketsandMarkets

Immunoassay Market - Global Forecast to 2026

発刊日 2021/04

言語英語

体裁PDF/395ページ

ライセンス/価格395ページ

0000029350

Single
5-user
Corporate
Global

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

無料サンプル

  • サンプルはお問い合わせください。

レポート概要

免疫アッセイ市場:製品別(試薬&キット、アナライザー)、技術別(ELISA、IFA、迅速検査、ラジオイムノアッセイ)、検体別(血液、唾液、尿)、用途別(感染症、腫瘍)、エンドユーザー別(病院&クリニック)- 2026年までの世界予測

世界の免疫アッセイ市場は、2021年の284億ドルから2026年までに390億ドルに達し、予測期間中のCAGRは6.6%と予想されます。免疫アッセイ市場の成長を促す主な要因は、慢性および感染性疾患の発生率の上昇です。進歩を続ける免疫アッセイの技術と免疫アッセイ製品の普及拡大が市場の成長を後押ししています。

アジア諸国の新興市場は、この市場のプレーヤーに強力な成長機会をもたらすものと期待されています。一方で、免疫アッセイ製品の厳しい規制シナリオと技術的ハードルが市場の成長をある程度抑制する可能性があります。免疫アッセイ市場は、製品別、技術別、検体別、用途別、エンドユーザー別、地域別に分類されます。

COVID-19が、免疫アッセイ市場に及ぼす影響

免疫アッセイ製品は、COVID-19の蔓延を抑える上で重要な役割を果たします。ワクチンや治療法がない場合、診断は、感染の大量拡散や想定される原因を制御および管理するための唯一の効果的な方法です。迅速検査は、COVID-19を大規模に監視するための効果的で迅速かつ簡単な分子検査として登場しました。複数の免疫アッセイの消耗品や分析装置の大規模な研究、評価、承認によって、SARS-CoV2検出の問題が軽減されました。化学発光、酵素結合、側方流動ベースのポイントオブケア検査、迅速検査、その他の技術などの免疫アッセイの使用が急増しています。

免疫アッセイ製品の承認に関する厳格な規制手順と、免疫アッセイキットおよび試薬の技術的ハードルが市場に影響を与えています。パンデミックの中で、一部の国ではCOVID-19の大規模な診断により、免疫アッセイ市場は大きな成長を遂げています。さらに、第3波のCOVID-19症例数の増加に伴い、市場はさらに拡大すると予想されます。

レポート詳細

目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 44)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
FIGURE 1 IMMUNOASSAY: MARKET SEGMENTATION
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 48)
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 3 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 5 BOTTOM-UP APPROACH
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 7 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ANALYSIS
2.5 ASSUMPTIONS FOR THE STUDY
2.6 COVID-19 ECONOMIC ASSESSMENT
2.7 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
FIGURE 9 CRITERIA IMPACTING THE GLOBAL ECONOMY
FIGURE 10 RECOVERY SCENARIO OF THE GLOBAL ECONOMY

3 EXECUTIVE SUMMARY (Page No. - 61)
FIGURE 11 IMMUNOASSAY MARKET, BY PRODUCT, 2021 VS. 2026 (USD BILLION)
FIGURE 12 IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD BILLION)
FIGURE 13 IMMUNOASSAY MARKET, BY SPECIMEN, 2021 VS. 2026 (USD BILLION)
FIGURE 14 IMMUNOASSAY MARKET, BY APPLICATION, 2021 VS. 2026 (USD BILLION)
FIGURE 15 IMMUNOASSAY MARKET, BY END USER, 2021 VS. 2026 (USD BILLION)
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF THE IMMUNOASSAY MARKET

4 PREMIUM INSIGHTS (Page No. - 67)
4.1 IMMUNOASSAY MARKET OVERVIEW
FIGURE 17 RISING DISEASE INCIDENCE AND TECHNOLOGICAL ADVANCEMENTS, THE KEY DRIVERS OF MARKET GROWTH
4.2 IMMUNOASSAY MARKET, BY PRODUCT (2021-2026)
FIGURE 18 REAGENTS & KITS TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
4.3 GEOGRAPHICAL SNAPSHOT OF THE IMMUNOASSAY MARKET
FIGURE 19 CHINA & INDIA TO WITNESS THE HIGHEST GROWTH RATES IN THE IMMUNOASSAY MARKET FROM 2021 TO 2026
4.4 GEOGRAPHIC MIX: IMMUNOASSAY MARKET
FIGURE 20 APAC TO WITNESS THE HIGHEST GROWTH IN THE FORECAST PERIOD
4.5 IMMUNOASSAY MARKET: DEVELOPED VS. DEVELOPING MARKETS
FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 72)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 22 IMMUNOASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing incidence of chronic and infectious diseases, and growing awareness about early disease diagnosis
FIGURE 23 INCIDENCE OF DIABETES, BY REGION, 2019, 2030, AND 2045
TABLE 1 GLOBAL INCIDENCE OF INFECTIOUS DISEASES
5.2.1.1.1 Increasing use of immunoassays in oncology
TABLE 2 GLOBAL INCIDENCE OF THE TOP CANCERS IN MEN
TABLE 3 GLOBAL INCIDENCE OF THE TOP CANCERS IN WOMEN
5.2.1.1.2 Immunoassays for COVID-19 and other viral diagnostics
5.2.1.1.3 Immunoassays in drug detection and other diagnostic applications
TABLE 4 DETECTION OF DRUGS BY URINE TESTING
5.2.1.1.4 Growing geriatric population
FIGURE 24 GLOBAL AGING POPULATION, BY REGION, 2019 VS. 2050 (MILLION)
5.2.1.2 Advancements in systems and technologies
5.2.1.3 Growth in the biotechnology and biopharmaceutical industries
5.2.1.4 Increasing adoption of immunoassay-based POC testing and rapid testing
5.2.1.4.1 Increasing drug and alcohol abuse, stringent laws mandating drug and alcohol testing
5.2.2 RESTRAINTS
5.2.2.1 Stringent requirements for the approval of immunoassay instruments and consumables
5.2.2.2 Technical hurdles of immunoassay kits
5.2.3 OPPORTUNITIES
5.2.3.1 Growth opportunities in emerging economies
5.2.3.2 Importance of companion diagnostics in the immunoassay market
TABLE 5 COMPANION DIAGNOSTIC ASSAYS APPROVED AND LAUNCHED
5.2.3.3 Development of condition-specific biomarkers and tests
TABLE 6 NEW TESTS LAUNCHED BY KEY PLAYERS
5.2.3.4 Integration of microfluidics in immunoassays
5.2.3.5 Improving immunoassay diagnostics technologies
5.2.4 CHALLENGES
5.2.4.1 Design challenges, complexities, and the quality of antibodies
5.2.4.2 The dearth of skilled professionals
5.2.4.3 Unfavorable reimbursement scenario
5.2.4.4 Financial hurdles faced by the physicians
5.3 COVID-19 IMPACT ON THE IMMUNOASSAY MARKET
FIGURE 25 KEY PLAYERS: REVENUE IMPACT
5.4 REGULATORY OVERVIEW
5.4.1 US
TABLE 7 US: CLASSIFICATION OF IMMUNOASSAY PRODUCTS
FIGURE 26 US: REGULATORY PROCESS FOR IVD DEVICES
5.4.2 CANADA
FIGURE 27 CANADA: REGULATORY PROCESS FOR IVD DEVICES IN CANADA
5.4.3 EUROPE
TABLE 8 EUROPE: CLASSIFICATION OF IVD DEVICES
5.4.3.1 Europe: Regulatory Process for IVD Devices
5.4.4 JAPAN
5.4.4.1 Japan: Regulatory Process for IVD Devices
TABLE 9 JAPAN: CLASSIFICATION OF IVD REAGENTS IN JAPAN
TABLE 10 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.4.5 CHINA
TABLE 11 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.4.6 INDIA
5.4.6.1 India: Regulatory Process for IVD Devices
5.4.7 INDONESIA
TABLE 12 INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES
5.4.8 RUSSIA
TABLE 13 RUSSIA: CLASSIFICATION OF IVD DEVICES
5.4.9 SAUDI ARABIA
TABLE 14 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.4.10 MEXICO
5.4.10.1 Mexico: Regulatory Process for IVD Devices
TABLE 15 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.4.11 BRAZIL
5.4.11.1 Brazil: Regulatory Process for IVD Devices
5.4.12 SOUTH KOREA
TABLE 16 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.5 TECHNOLOGY ANALYSIS
TABLE 17 CONVENTIONAL IMMUNOASSAYS METHODS AND TECHNIQUES
TABLE 18 RECENT PRODUCT LAUNCHES WITH ADVANCED TECHNOLOGIES IN THE IMMUNOASSAY MARKET
5.6 PRICING ANALYSIS
5.6.1 AVERAGE SELLING PRICE
TABLE 19 IMMUNOASSAY: AVERAGE SELLING PRICE IN 2021
5.7 TRADE ANALYSIS
5.7.1 TRADE ANALYSIS FOR IMMUNOASSAYS
TABLE 20 IMPORT DATA FOR INSTRUMENTS AND APPARATUS FOR PHYSICAL OR CHEMICAL ANALYSIS OR FOR MEASURING OR CHECKING VISCOSITY, POROSITY, EXPANSION, SURFACE TENSION OR THE LIKE, OR FOR MEASURING OR CHECKING QUANTITIES OF HEAT, SOUND, OR LIGHT, N.E.S., BY COUNTRY, 2016-2020 (USD MILLION)
TABLE 21 EXPORT DATA FOR INSTRUMENTS AND APPARATUS FOR PHYSICAL OR CHEMICAL ANALYSIS OR FOR MEASURING OR CHECKING VISCOSITY, POROSITY, EXPANSION, SURFACE TENSION OR THE LIKE, OR FOR MEASURING OR CHECKING QUANTITIES OF HEAT, SOUND, OR LIGHT, N.E.S, 2016-2020 (USD MILLION)
5.8 PATENT ANALYSIS
TABLE 22 LIST OF PATENTS
5.9 VALUE CHAIN ANALYSIS
FIGURE 28 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASES
5.10 SUPPLY CHAIN ANALYSIS
FIGURE 29 DIRECT DISTRIBUTION, THE PREFERRED STRATEGY FOR PROMINENT COMPANIES
5.11 ECOSYSTEM ANALYSIS OF THE IMMUNOASSAY MARKET
FIGURE 30 ECOSYSTEM ANALYSIS OF THE IMMUNOASSAY MARKET
5.11.1 ROLE IN THE ECOSYSTEM
5.12 PORTER’S FIVE FORCES ANALYSIS
TABLE 23 HIGH CONSOLIDATION IN THE MARKET TO RESTRICT THE ENTRY OF NEW PLAYERS
5.12.1 DEGREE OF COMPETITION
5.12.2 BARGAINING POWER OF SUPPLIERS
5.12.3 BARGAINING POWER OF BUYERS
5.12.4 THREAT OF SUBSTITUTES
5.12.5 THREAT OF NEW ENTRANTS

6 IMMUNOASSAY MARKET, BY PRODUCT (Page No. - 108)
6.1 INTRODUCTION
TABLE 24 IMMUNOASSAY MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
6.2 REAGENTS & KITS
TABLE 25 IMMUNOASSAY REAGENTS & KITS AVAILABLE IN THE MARKET
TABLE 26 IMMUNOASSAY REAGENTS & KITS MARKET, BY REGION, 2018-2026 (USD MILLION)
TABLE 27 IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018-2026 (USD MILLION)
6.2.1 ELISA REAGENTS & KITS
6.2.1.1 Elisa reagents & kits are widely used in basic research and high-throughput screening
TABLE 28 ELISA REAGENTS & KITS MARKET, BY REGION, 2018-2026 (USD MILLION)
6.2.2 RAPID TEST REAGENTS & KITS
6.2.2.1 Demand for rapid test reagents & kits is especially high in remote areas or cases where advanced equipment is unavailable
TABLE 29 RAPID TEST REAGENTS & KITS MARKET, BY REGION, 2018-2026 (USD MILLION)
6.2.3 ELISPOT REAGENTS & KITS
6.2.3.1 The rising prevalence of infectious diseases drives the market growth
TABLE 30 ELISPOT REAGENTS & KITS MARKET, BY REGION, 2018-2026 (USD MILLION)
6.2.4 WESTERN BLOT REAGENTS & KITS
6.2.4.1 Western blotting is considered the gold standard for confirmation
TABLE 31 WESTERN BLOT REAGENTS & KITS MARKET, BY REGION, 2018-2026 (USD MILLION)
6.2.4.2 Other reagents & kits
TABLE 32 OTHER REAGENTS & KITS MARKET, BY REGION, 2018-2026 (USD MILLION)
6.3 ANALYZERS
TABLE 33 IMMUNOASSAY ANALYZERS AVAILABLE IN THE MARKET
TABLE 34 IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2018-2026 (USD MILLION)
6.3.1 IMMUNOASSAY ANALYZERS MARKET, BY TYPE
TABLE 35 IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018-2026 (USD MILLION)
6.3.1.1 Open-ended systems
6.3.1.1.1 Flexibility and wide availability make open-ended systems popular among users
TABLE 36 OPEN-ENDED SYSTEMS MARKET, BY REGION, 2018-2026 (USD MILLION)
6.3.1.2 Closed-ended systems
6.3.1.2.1 High precision and automation are key features of closed-ended systems
TABLE 37 CLOSED-ENDED SYSTEMS MARKET, BY REGION, 2018-2026 (USD MILLION)
6.3.2 IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE
TABLE 38 IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018-2026 (USD MILLION)
6.3.2.1 Rental purchase
6.3.2.1.1 Convenience and lack of liability for end users drive preference for device rental
TABLE 39 IMMUNOASSAY ANALYZERS MARKET FOR RENTAL PURCHASE, BY REGION, 2018-2026 (USD MILLION)
6.3.2.2 Outright purchase
6.3.2.2.1 Outright purchase is favored by government organizations, big companies, and CROs
TABLE 40 IMMUNOASSAY ANALYZERS MARKET FOR OUTRIGHT PURCHASE, BY REGION, 2018-2026 (USD MILLION)

7 IMMUNOASSAY MARKET, BY TECHNOLOGY (Page No. - 122)
7.1 INTRODUCTION
TABLE 41 IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
7.2 ELISA
TABLE 42 KEY ELISA SYSTEMS AVAILABLE IN THE MARKET
TABLE 43 ELISA MARKET, BY REGION, 2018-2026 (USD MILLION)
7.2.1 ELISA MARKET, BY GENERATION
TABLE 44 ELISA MARKET, BY GENERATION, 2018-2026 (USD MILLION)
7.2.1.1 Third-generation & Above
7.2.1.1.1 Third and fourth-gen ELISA show high specificity and accuracy, leading to their wide use
TABLE 45 THIRD-GENERATION & ABOVE ELISA MARKET, BY REGION, 2018-2026 (USD MILLION)
7.2.1.2 Second-generation & below
7.2.1.2.1 The cost-effectiveness of the first and second-gen tests supports their use, especially in developing countries
TABLE 46 SECOND-GENERATION & BELOW ELISA MARKET, BY REGION, 2018-2026 (USD MILLION)
7.2.2 ELISA MARKET, BY TYPE
TABLE 47 ELISA MARKET, BY TYPE, 2018-2026 (USD MILLION)
7.2.2.1 CLIA
7.2.2.1.1 CLIA holds the largest share of the ELISA market, by type
TABLE 48 CLIA MARKET, BY REGION, 2018-2026 (USD MILLION)
7.2.2.2 IFA
7.2.2.2.1 IFA is used to diagnose antibodies against infectious pathogens
TABLE 49 IFA MARKET, BY REGION, 2018-2026 (USD MILLION)
7.2.2.3 Colorimetric immunoassays
7.2.2.3.1 The introduction of advanced techniques will support market growth
TABLE 50 COLORIMETRIC IMMUNOASSAYS MARKET, BY REGION, 2018-2026 (USD MILLION)
7.3 RAPID TESTS
7.3.1 RAPID TESTS ARE HIGHLY USEFUL IN UNDERDEVELOPED/EMERGING COUNTRIES OR AREAS WITH LIMITED ACCESSIBILITY TO SOPHISTICATED TECHNOLOGIES
TABLE 51 KEY RAPID TESTS AVAILABLE IN THE MARKET
TABLE 52 RAPID TESTS MARKET, BY REGION, 2018-2026 (USD MILLION)
7.4 WESTERN BLOTTING
7.4.1 WESTERN BLOTTING IS WIDELY USED FOR TEST CONFIRMATION
TABLE 53 WESTERN BLOTTING SYSTEMS AVAILABLE IN THE MARKET
TABLE 54 WESTERN BLOTTING MARKET, BY REGION, 2018-2026 (USD MILLION)
7.5 RADIOIMMUNOASSAYS
7.5.1 RIA ARE WIDELY USED FOR DIAGNOSIS AND DRUG TESTING
TABLE 55 RADIOIMMUNOASSAY MARKET, BY REGION, 2018-2026 (USD MILLION)
7.6 ELISPOT
7.6.1 HIGH SENSITIVITY, SPECIFICITY, AND VERSATILITY OF ELISPOT DRIVES ADOPTION OF ASSAYS
TABLE 56 ELISPOT MARKET, BY REGION, 2018-2026 (USD MILLION)
7.7 OTHER TECHNOLOGIES
TABLE 57 OTHER IMMUNOASSAY TECHNOLOGIES MARKET, BY REGION, 2018-2026 (USD MILLION)

8 IMMUNOASSAY MARKET, BY SPECIMEN (Page No. - 136)
8.1 INTRODUCTION
TABLE 58 IMMUNOASSAY MARKET, BY SPECIMEN, 2018-2026 (USD MILLION)
8.2 BLOOD
8.2.1 RELIABILITY OF BLOOD TESTS WILL ENSURE STABLE MARKET GROWTH, DESPITE INTRODUCTION OF TESTS USING OTHER SPECIMEN TYPES
TABLE 59 IMMUNOASSAY MARKET FOR BLOOD SPECIMENS, BY REGION, 2018-2026 (USD MILLION)
8.3 SALIVA
8.3.1 CONVENIENCE AND APPLICATIONS OF SALIVA TESTS TO SUPPORT THE MARKET GROWTH
TABLE 60 IMMUNOASSAY MARKET FOR SALIVA SPECIMENS, BY REGION, 2018-2026 (USD MILLION)
8.4 URINE
8.4.1 USE IN LAW ENFORCEMENT AND DRUG TESTING APPLICATIONS DRIVES DEMAND FOR URINE-BASED TESTS
TABLE 61 IMMUNOASSAY MARKET FOR URINE SPECIMENS, BY REGION, 2018-2026 (USD MILLION)
8.5 OTHER SPECIMENS
TABLE 62 IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY REGION, 2018-2026 (USD MILLION)

9 IMMUNOASSAY MARKET, BY APPLICATION (Page No. - 142)
9.1 INTRODUCTION
TABLE 63 IMMUNOASSAY MARKET, BY APPLICATION, 2018-2026 (USD MILLION)
9.2 INFECTIOUS DISEASES
9.2.1 RISING PREVALENCE OF INFECTIOUS DISEASES, DEMAND FOR COVID-19 DIAGNOSTICS DRIVE MARKET GROWTH
TABLE 64 IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2018-2026 (USD MILLION)
9.3 ENDOCRINOLOGY
9.3.1 RISING DIABETES INCIDENCE DRIVES DEMAND FOR IMMUNOASSAYS
TABLE 65 IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY REGION, 2018-2026 (USD MILLION)
9.4 CARDIOLOGY
9.4.1 INCREASING PREVALENCE OF CVD DRIVES MARKET GROWTH
TABLE 66 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR CARDIOLOGY
TABLE 67 IMMUNOASSAY MARKET FOR CARDIOLOGY, BY REGION, 2018-2026 (USD MILLION)
9.5 AUTOIMMUNE DISORDERS
9.5.1 HIGH PREVALENCE OF AUTOIMMUNE DISEASES AND RISING ECONOMIC BURDEN OF TREATMENT
TABLE 68 INCIDENCE OF AUTOIMMUNE DISEASES, BY TYPE
TABLE 69 IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2018-2026 (USD MILLION)
9.6 ALLERGY DIAGNOSTICS
9.6.1 PREVALENCE OF ALLERGIES EXPECTED TO REGISTER DRASTIC INCREASE
TABLE 70 IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2018-2026 (USD MILLION)
9.7 ONCOLOGY
9.7.1 RISING BURDEN OF CANCER AND GROWING GERIATRIC POPULATION SUPPORT MARKET GROWTH
TABLE 71 US CANCER INCIDENCE, BY TYPE, 2018 VS 2025
TABLE 72 IMMUNOASSAY MARKET FOR ONCOLOGY, BY REGION, 2018-2026 (USD MILLION)
9.8 BONE & MINERAL DISORDERS
9.8.1 HIGH DISORDER PREVALENCE INDICATES STRONG GROWTH OPPORTUNITIES FOR IMMUNOASSAYS
TABLE 73 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR BONE & MINERAL DISORDER DIAGNOSIS
TABLE 74 IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY REGION, 2018-2026 (USD MILLION)
9.9 TOXICOLOGY
9.9.1 RISING DRUG ABUSE AND ILLICIT DRUG CONSUMPTION ENSURE DEMAND FOR IMMUNOASSAYS IN TOXICOLOGY
TABLE 75 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR DRUG MONITORING
TABLE 76 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR DRUGS-OF-ABUSE/TOXICOLOGY ASSAYS
TABLE 77 IMMUNOASSAY MARKET FOR TOXICOLOGY, BY REGION, 2018-2026 (USD MILLION)
9.10 BLOOD SCREENING
9.10.1 RISING BLOOD DONATION VOLUMES FAVOR DEMAND FOR IMMUNOASSAYS
TABLE 78 IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY REGION, 2018-2026 (USD MILLION)
9.11 NEWBORN SCREENING
9.11.1 IMMUNOASSAYS ARE USED AS A FIRST-TIER NEWBORN SCREENING PROTOCOL
TABLE 79 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR NEWBORN SCREENING
TABLE 80 IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY REGION, 2018-2026 (USD MILLION)
9.12 OTHER APPLICATIONS
TABLE 81 IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY REGION, 2018-2026 (USD MILLION)

10 IMMUNOASSAY MARKET, BY END USER (Page No. - 157)
10.1 INTRODUCTION
TABLE 82 IMMUNOASSAY MARKET, BY END USER, 2018-2026 (USD MILLION)
10.2 HOSPITALS & CLINICS
10.2.1 GROWING PATIENT POPULATION AND TESTING VOLUMES DRIVE MARKET GROWTH
TABLE 83 IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY REGION, 2018-2026 (USD MILLION)
10.3 CLINICAL LABORATORIES
10.3.1 RISING CLINICAL TEST VOLUMES AND REQUIREMENTS SUPPORT USE OF IMMUNOASSAYS IN CLINICAL LABS
TABLE 84 IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY REGION, 2018-2026 (USD MILLION)
10.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS
10.4.1 GROWING DRUG DISCOVERY AND CLINICAL STUDY ACTIVITY DRIVE DEMAND FOR IMMUNOASSAYS IN PHARMA-BIOTECH INDUSTRY
TABLE 85 IMMUNOASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS, BY REGION, 2018-2026 (USD MILLION)
10.5 HOME CARE SETTINGS
10.5.1 RELIANCE ON AT-HOME TESTS AND POC DIAGNOSTICS BOOSTS MARKET GROWTH
TABLE 86 IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY REGION, 2018-2026 (USD MILLION)
10.6 BLOOD BANKS
10.6.1 RISING DEMAND FOR BLOOD AND GROWING BLOOD DONATION VOLUMES DRIVE USE OF IMMUNOASSAYS FOR SCREENING
TABLE 87 IMMUNOASSAY MARKET FOR BLOOD BANKS, BY REGION, 2018-2026 (USD MILLION)
10.7 RESEARCH & ACADEMIC LABORATORIES
10.7.1 RISING NUMBER OF COLLEGES & UNIVERSITIES DRIVES MARKET GROWTH
TABLE 88 IMMUNOASSAY MARKET FOR RESEARCH & ACADEMIC LABORATORIES, BY REGION, 2018-2026 (USD MILLION

11 IMMUNOASSAY MARKET, BY REGION (Page No. - 166)
11.1 INTRODUCTION
TABLE 89 IMMUNOASSAY MARKET, BY REGION, 2018-2026 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 31 NORTH AMERICA: IMMUNOASSAY MARKET SNAPSHOT
TABLE 90 NORTH AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 91 NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 92 NORTH AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 93 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 94 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018-2026 (USD MILLION)
TABLE 95 NORTH AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
TABLE 96 NORTH AMERICA: ELISA MARKET, BY GENERATION, 2018-2026 (USD MILLION)
TABLE 97 NORTH AMERICA: ELISA MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 98 NORTH AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2018-2026 (USD MILLION)
TABLE 99 NORTH AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 100 NORTH AMERICA: IMMUNOASSAY MARKET, BY END USER, 2018-2026 (USD MILLION)
11.2.1 US
11.2.1.1 The US dominates the North American market
TABLE 101 US: IMMUNOASSAY MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 102 US: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 103 US: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 104 US: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018-2026 (USD MILLION)
TABLE 105 US: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
TABLE 106 US: ELISA MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 107 US: IMMUNOASSAY MARKET, BY SPECIMEN, 2018-2026 (USD MILLION)
TABLE 108 US: IMMUNOASSAY MARKET, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 109 US: IMMUNOASSAY MARKET, BY END USER, 2018-2026 (USD MILLION)
11.2.2 CANADA
TABLE 110 CANADA: IMMUNOASSAY MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 111 CANADA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 112 CANADA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 113 CANADA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018-2026 (USD MILLION)
TABLE 114 CANADA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
TABLE 115 CANADA: ELISA MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 116 CANADA: IMMUNOASSAY MARKET, BY SPECIMEN, 2018-2026 (USD MILLION)
TABLE 117 CANADA: IMMUNOASSAY MARKET, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 118 CANADA: IMMUNOASSAY MARKET, BY END USER, 2018-2026 (USD MILLION)
11.3 EUROPE
FIGURE 32 EUROPE: IMMUNOASSAY MARKET SNAPSHOT
TABLE 119 EUROPE: IMMUNOASSAY MARKET, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 120 EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 121 EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 122 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 123 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018-2026 (USD MILLION)
TABLE 124 EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
TABLE 125 EUROPE: ELISA MARKET, BY GENERATION, 2018-2026 (USD MILLION)
TABLE 126 EUROPE: ELISA MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 127 EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2018-2026 (USD MILLION)
TABLE 128 EUROPE: IMMUNOASSAY MARKET, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 129 EUROPE: IMMUNOASSAY MARKET, BY END USER, 2018-2026 (USD MILLION)
11.3.1 GERMANY
11.3.1.1 Germany holds the largest share of the EU immunoassay market
TABLE 130 GERMANY: IMMUNOASSAY MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 131 GERMANY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 132 GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 133 GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018-2026 (USD MILLION)
TABLE 134 GERMANY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
TABLE 135 GERMANY: ELISA MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 136 GERMANY: IMMUNOASSAY MARKET, BY SPECIMEN, 2018-2026 (USD MILLION)
TABLE 137 GERMANY: IMMUNOASSAY MARKET, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 138 GERMANY: IMMUNOASSAY MARKET, BY END USER, 2018-2026 (USD MILLION)
11.3.2 ITALY
11.3.2.1 Growing geriatric population and increasing support for research drives market growth
TABLE 139 ITALY: IMMUNOASSAY MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 140 ITALY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 141 ITALY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 142 ITALY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018-2026 (USD MILLION)
TABLE 143 ITALY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
TABLE 144 ITALY: ELISA MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 145 ITALY: IMMUNOASSAY MARKET, BY SPECIMEN, 2018-2026 (USD MILLION)
TABLE 146 ITALY: IMMUNOASSAY MARKET, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 147 ITALY: IMMUNOASSAY MARKET, BY END USER, 2018-2026 (USD MILLION)
11.3.3 FRANCE
11.3.3.1 Rising use of POC testing and favorable reimbursement policy contribute to market growth in France
TABLE 148 FRANCE: IMMUNOASSAY MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 149 FRANCE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 150 FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 151 FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018-2026 (USD MILLION)
TABLE 152 FRANCE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
TABLE 153 FRANCE: ELISA MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 154 FRANCE: IMMUNOASSAY MARKET, BY SPECIMEN, 2018-2026 (USD MILLION)
TABLE 155 FRANCE: IMMUNOASSAY MARKET, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 156 FRANCE: IMMUNOASSAY MARKET, BY END USER, 2018-2026 (USD MILLION)
11.3.4 SPAIN
11.3.4.1 Growth of the geriatric population and rising demand for testing support the market in Spain
TABLE 157 SPAIN: IMMUNOASSAY MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 158 SPAIN: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 159 SPAIN: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 160 SPAIN: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018-2026 (USD MILLION)
TABLE 161 SPAIN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
TABLE 162 SPAIN: ELISA MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 163 SPAIN: IMMUNOASSAY MARKET, BY SPECIMEN, 2018-2026 (USD MILLION)
TABLE 164 SPAIN: IMMUNOASSAY MARKET, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 165 SPAIN: IMMUNOASSAY MARKET, BY END USER, 2018-2026 (USD MILLION)
11.3.5 UK
11.3.5.1 Government support for disease diagnostics and favorable investment scenario drive the market in the UK
TABLE 166 UK: IMMUNOASSAY MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 167 UK: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 168 UK: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 169 UK: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018-2026 (USD MILLION)
TABLE 170 UK: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
TABLE 171 UK: ELISA MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 172 UK: IMMUNOASSAY MARKET, BY SPECIMEN, 2018-2026 (USD MILLION)
TABLE 173 UK: IMMUNOASSAY MARKET, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 174 UK: IMMUNOASSAY MARKET, BY END USER, 2018-2026 (USD MILLION)
11.3.6 RUSSIA
11.3.6.1 Lack of reimbursement and delays in approval may hinder the market growth
TABLE 175 RUSSIA: IMMUNOASSAY MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 176 RUSSIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 177 RUSSIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 178 RUSSIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018-2026 (USD MILLION)
TABLE 179 RUSSIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
TABLE 180 RUSSIA: ELISA MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 181 RUSSIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2018-2026 (USD MILLION)
TABLE 182 RUSSIA: IMMUNOASSAY MARKET, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 183 RUSSIA: IMMUNOASSAY MARKET, BY END USER, 2018-2026 (USD MILLION)
11.3.7 REST OF EUROPE
TABLE 184 ROE: IMMUNOASSAY MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 185 ROE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 186 ROE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 187 ROE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018-2026 (USD MILLION)
TABLE 188 ROE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
TABLE 189 ROE: ELISA MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 190 ROE: IMMUNOASSAY MARKET, BY SPECIMEN, 2018-2026 (USD MILLION)
TABLE 191 ROE: IMMUNOASSAY MARKET, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 192 ROE: IMMUNOASSAY MARKET, BY END USER, 2018-2026 (USD MILLION)
11.4 ASIA PACIFIC
FIGURE 33 ASIA PACIFIC: IMMUNOASSAY MARKET SNAPSHOT
TABLE 193 ASIA PACIFIC: IMMUNOASSAY MARKET, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 194 ASIA PACIFIC: IMMUNOASSAY MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 195 ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 196 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 197 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018-2026 (USD MILLION)
TABLE 198 ASIA PACIFIC: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
TABLE 199 ASIA PACIFIC: ELISA MARKET, BY GENERATION, 2018-2026 (USD MILLION)
TABLE 200 ASIA PACIFIC: ELISA MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 201 ASIA PACIFIC: IMMUNOASSAY MARKET, BY SPECIMEN, 2018-2026 (USD MILLION)
TABLE 202 ASIA PACIFIC: IMMUNOASSAY MARKET, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 203 ASIA PACIFIC: IMMUNOASSAY MARKET, BY END USER, 2018-2026 (USD MILLION)
11.4.1 JAPAN
11.4.1.1 Japan dominates the APAC market
TABLE 204 JAPAN: IMMUNOASSAY MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 205 JAPAN: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 206 JAPAN: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 207 JAPAN: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018-2026 (USD MILLION)
TABLE 208 JAPAN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
TABLE 209 JAPAN: ELISA MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 210 JAPAN: IMMUNOASSAY MARKET, BY SPECIMEN, 2018-2026 (USD MILLION)
TABLE 211 JAPAN: IMMUNOASSAY MARKET, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 212 JAPAN: IMMUNOASSAY MARKET, BY END USER, 2018-2026 (USD MILLION)
11.4.2 CHINA
11.4.2.1 Opportunities for growth in the Chinese market tempered by long product approval and registration processes
TABLE 213 CHINA: IMMUNOASSAY MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 214 CHINA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 215 CHINA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 216 CHINA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018-2026 (USD MILLION)
TABLE 217 CHINA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
TABLE 218 CHINA: ELISA MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 219 CHINA: IMMUNOASSAY MARKET, BY SPECIMEN, 2018-2026 (USD MILLION)
TABLE 220 CHINA: IMMUNOASSAY MARKET, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 221 CHINA: IMMUNOASSAY MARKET, BY END USER, 2018-2026 (USD MILLION)
11.4.3 INDIA
11.4.3.1 Growing medical tourism and healthcare infrastructure will drive the use of immunoassays in India
TABLE 222 INDIA: IMMUNOASSAY MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 223 INDIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 224 INDIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 225 INDIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018-2026 (USD MILLION)
TABLE 226 INDIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
TABLE 227 INDIA: ELISA MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 228 INDIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2018-2026 (USD MILLION)
TABLE 229 INDIA: IMMUNOASSAY MARKET, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 230 INDIA: IMMUNOASSAY MARKET, BY END USER, 2018-2026 (USD MILLION)
11.4.4 AUSTRALIA
11.4.4.1 Growing disease incidence and technological development drive market growth
TABLE 231 AUSTRALIA: IMMUNOASSAY MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 232 AUSTRALIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 233 AUSTRALIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 234 AUSTRALIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018-2026 (USD MILLION)
TABLE 235 AUSTRALIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
TABLE 236 AUSTRALIA: ELISA MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 237 AUSTRALIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2018-2026 (USD MILLION)
TABLE 238 AUSTRALIA: IMMUNOASSAY MARKET, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 239 AUSTRALIA: IMMUNOASSAY MARKET, BY END USER, 2018-2026 (USD MILLION)
11.4.5 SOUTH KOREA
11.4.5.1 Rising healthcare spending and investments in research are driving market growth
TABLE 240 SOUTH KOREA: IMMUNOASSAY MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 241 SOUTH KOREA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 242 SOUTH KOREA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 243 SOUTH KOREA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018-2026 (USD MILLION)
TABLE 244 SOUTH KOREA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
TABLE 245 SOUTH KOREA: ELISA MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 246 SOUTH KOREA: IMMUNOASSAY MARKET, BY SPECIMEN, 2018-2026 (USD MILLION)
TABLE 247 SOUTH KOREA: IMMUNOASSAY MARKET, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 248 SOUTH KOREA: IMMUNOASSAY MARKET, BY END USER, 2018-2026 (USD MILLION)
11.4.6 INDONESIA
11.4.6.1 Indonesia has become a promising market and growth hotspot for foreign investors
TABLE 249 INDONESIA: IMMUNOASSAY MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 250 INDONESIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 251 INDONESIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 252 INDONESIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018-2026 (USD MILLION)
TABLE 253 INDONESIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
TABLE 254 INDONESIA: ELISA MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 255 INDONESIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2018-2026 (USD MILLION)
TABLE 256 INDONESIA: IMMUNOASSAY MARKET, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 257 INDONESIA: IMMUNOASSAY MARKET, BY END USER, 2018-2026 (USD MILLION)
11.4.7 REST OF ASIA PACIFIC
TABLE 258 ROAPAC: IMMUNOASSAY MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 259 ROAPAC: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 260 ROAPAC: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 261 ROAPAC: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018-2026 (USD MILLION)
TABLE 262 ROAPAC: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
TABLE 263 ROAPAC: ELISA MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 264 ROAPAC: IMMUNOASSAY MARKET, BY SPECIMEN, 2018-2026 (USD MILLION)
TABLE 265 ROAPAC: IMMUNOASSAY MARKET, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 266 ROAPAC: IMMUNOASSAY MARKET, BY END USER, 2018-2026 (USD MILLION)
11.5 LATIN AMERICA
TABLE 267 LATIN AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 268 LATIN AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 269 LATIN AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 270 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 271 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018-2026 (USD MILLION)
TABLE 272 LATIN AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
TABLE 273 LATIN AMERICA: ELISA MARKET, BY GENERATION, 2018-2026 (USD MILLION)
TABLE 274 LATIN AMERICA: ELISA MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 275 LATIN AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2018-2026 (USD MILLION)
TABLE 276 LATIN AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 277 LATIN AMERICA: IMMUNOASSAY MARKET, BY END USER, 2018-2026 (USD MILLION)
11.5.1 BRAZIL
11.5.1.1 Brazil held the largest share of the LATAM market in 2020
TABLE 278 BRAZIL: IMMUNOASSAY TESTS APPROVED BY ANVISA FOR COVID-19 APPLICATIONS
TABLE 279 BRAZIL: IMMUNOASSAY MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 280 BRAZIL: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 281 BRAZIL: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 282 BRAZIL: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018-2026 (USD MILLION)
TABLE 283 BRAZIL: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
TABLE 284 BRAZIL: ELISA MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 285 BRAZIL: IMMUNOASSAY MARKET, BY SPECIMEN, 2018-2026 (USD MILLION)
TABLE 286 BRAZIL: IMMUNOASSAY MARKET, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 287 BRAZIL: IMMUNOASSAY MARKET, BY END USER, 2018-2026 (USD MILLION)
11.5.2 MEXICO
11.5.2.1 Growing lab consolidation is expected to reduce the number of labs in Mexico
TABLE 288 MEXICO: IMMUNOASSAY MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 289 MEXICO: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 290 MEXICO: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 291 MEXICO: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018-2026 (USD MILLION)
TABLE 292 MEXICO: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
TABLE 293 MEXICO: ELISA MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 294 MEXICO: IMMUNOASSAY MARKET, BY SPECIMEN, 2018-2026 (USD MILLION)
TABLE 295 MEXICO: IMMUNOASSAY MARKET, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 296 MEXICO: IMMUNOASSAY MARKET, BY END USER, 2018-2026 (USD MILLION)
11.5.3 REST OF LATIN AMERICA
TABLE 297 ROLATAM: IMMUNOASSAY MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 298 ROLATAM: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 299 ROLATAM: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 300 ROLATAM: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018-2026 (USD MILLION)
TABLE 301 ROLATAM: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
TABLE 302 ROLATAM: ELISA MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 303 ROLATAM: IMMUNOASSAY MARKET, BY SPECIMEN, 2018-2026 (USD MILLION)
TABLE 304 ROLATAM: IMMUNOASSAY MARKET, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 305 ROLATAM: IMMUNOASSAY MARKET, BY END USER, 2018-2026 (USD MILLION)
11.6 MIDDLE EAST & AFRICA
11.6.1 MEA ACCOUNTS FOR A SMALL SHARE OF THE GLOBAL MARKET
TABLE 306 MEA: IMMUNOASSAY MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 307 MEA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 308 MEA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 309 MEA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2018-2026 (USD MILLION)
TABLE 310 MEA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
TABLE 311 MEA: ELISA MARKET, BY GENERATION, 2018-2026 (USD MILLION)
TABLE 312 MEA: ELISA MARKET, BY TYPE, 2018-2026 (USD MILLION)
TABLE 313 MEA: IMMUNOASSAY MARKET, BY SPECIMEN, 2018-2026 (USD MILLION)
TABLE 314 MEA: IMMUNOASSAY MARKET, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 315 MEA: IMMUNOASSAY MARKET, BY END USER, 2018-2026 (USD MILLION)

12 COMPETITIVE LANDSCAPE (Page No. - 294)
12.1 OVERVIEW
FIGURE 34 KEY DEVELOPMENTS IN THE IMMUNOASSAY MARKET, JANUARY 2017-APRIL 2021
FIGURE 35 MARKET EVALUATION MATRIX, 2017-2020
12.2 MARKET SHARE ANALYSIS
FIGURE 36 IMMUNOASSAY MARKET SHARE ANALYSIS, 2020
12.3 COMPANY EVALUATION QUADRANT
12.3.1 STARS
12.3.2 EMERGING LEADERS
12.3.3 PERVASIVE PLAYERS
12.3.4 PARTICIPANTS
FIGURE 37 IMMUNOASSAY MARKET: COMPANY EVALUATION QUADRANT
12.4 COMPANY EVALUATION QUADRANT (SMES/START-UPS)
12.4.1 PROGRESSIVE COMPANIES
12.4.2 STARTING BLOCKS
12.4.3 RESPONSIVE COMPANIES
12.4.4 DYNAMIC COMPANIES
FIGURE 38 IMMUNOASSAY MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES
12.5 COMPETITIVE SCENARIO
12.5.1 PRODUCT LAUNCHES & APPROVALS
TABLE 316 IMMUNOASSAY MARKET: PRODUCT LAUNCHES & APPROVALS, 2017-2021
12.5.2 DEALS
TABLE 317 IMMUNOASSAY MARKET: DEALS, 2017-2021
12.5.3 OTHER DEVELOPMENTS
TABLE 318 IMMUNOASSAY MARKET: OTHER DEVELOPMENTS, 2017-2021
12.6 COMPANY PRODUCT FOOTPRINT
FIGURE 39 PRODUCT PORTFOLIO ANALYSIS: IMMUNOASSAY MARKET
12.7 COMPANY GEOGRAPHIC FOOTPRINT
FIGURE 40 GEOGRAPHIC REVENUE MIX: IMMUNOASSAY MARKET (2020)

13 COMPANY PROFILES (Page No. - 306)
13.1 MAJOR PLAYERS
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
13.1.1 DANAHER CORPORATION
TABLE 319 DANAHER: BUSINESS OVERVIEW
FIGURE 41 DANAHER: COMPANY SNAPSHOT (2020)
13.1.2 THERMO FISHER SCIENTIFIC
TABLE 320 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
FIGURE 42 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2020)
13.1.3 ABBOTT LABORATORIES
TABLE 321 ABBOTT LABORATORIES: BUSINESS OVERVIEW
FIGURE 43 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020)
13.1.4 ROCHE DIAGNOSTICS
TABLE 322 F. HOFFMAN-LA ROCHE: BUSINESS OVERVIEW
FIGURE 44 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2020)
13.1.5 SIEMENS HEALTHINEERS
TABLE 323 SIEMENS HEALTHINEERS: BUSINESS OVERVIEW
FIGURE 45 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2020)
13.1.6 QUIDEL CORPORATION
TABLE 324 QUIDEL: BUSINESS OVERVIEW
FIGURE 46 QUIDEL: COMPANY SNAPSHOT (2020)
13.1.7 DIASORIN
TABLE 325 DIASORIN: BUSINESS OVERVIEW
FIGURE 47 DIASORIN: COMPANY SNAPSHOT (2019)
13.1.8 BIOMÉRIEUX
TABLE 326 BIOMÉRIEUX: BUSINESS OVERVIEW
FIGURE 48 BIOMÉRIEUX: COMPANY SNAPSHOT (2019)
13.1.9 BIO-RAD LABORATORIES
TABLE 327 BIO-RAD LABORATORIES: BUSINESS OVERVIEW
FIGURE 49 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2020)
13.1.10 ORTHO CLINICAL DIAGNOSTICS
TABLE 328 ORTHO CLINICAL DIAGNOSTICS: BUSINESS OVERVIEW
13.1.11 PERKINELMER
TABLE 329 PERKINELMER: BUSINESS OVERVIEW
FIGURE 50 PERKINELMER: COMPANY SNAPSHOT (2020)
13.1.12 BECTON, DICKINSON & COMPANY
TABLE 330 BD: BUSINESS OVERVIEW
FIGURE 51 BD: COMPANY SNAPSHOT (2020)
13.1.13 SYSMEX CORPORATION
TABLE 331 SYSMEX: BUSINESS OVERVIEW
FIGURE 52 SYSMEX CORPORATION: COMPANY SNAPSHOT (2019)
13.1.14 AGILENT TECHNOLOGIES
TABLE 332 AGILENT TECHNOLOGIES: BUSINESS OVERVIEW
FIGURE 53 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2020)
13.1.15 MINDRAY
TABLE 333 MINDRAY: BUSINESS OVERVIEW
13.1.16 QIAGEN
TABLE 334 QIAGEN: BUSINESS OVERVIEW
FIGURE 54 QIAGEN: COMPANY SNAPSHOT (2020)
13.2 OTHER COMPANIES/START-UPS
13.2.1 MERCK KGAA
13.2.2 BIO-TECHNE
13.2.3 CELLABS
13.2.4 ABNOVA CORPORATION
13.2.5 J. MITRA & CO.
13.2.6 TOSOH CORPORATION (TOSOH BIOSCIENCES)
13.2.7 CELL SCIENCES
13.2.8 ENZO BIOCHEM
13.2.9 CREATIVE DIAGNOSTICS
13.2.10 BOSTER BIOLOGICAL TECHNOLOGY
13.2.11 ELABSCIENCE
13.2.12 WAK-CHEMIE MEDICAL
13.2.13 SERA CARE
13.2.14 EPITOPE DIAGNOSTICS
13.2.15 KAMIYA BIOMEDICAL COMPANY
13.2.16 GYROS PROTEIN TECHNOLOGIES

*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.

14 APPENDIX (Page No. - 401)
14.1 INSIGHTS FROM INDUSTRY EXPERTS
14.2 DISCUSSION GUIDE
14.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.4 AVAILABLE CUSTOMIZATIONS
14.5 RELATED REPORTS
14.6 AUTHOR DETAILS

この商品のレポートナンバー

0000029350

TOP